Puzzling Over the Hurt Down-Under
Serious Mental Illness and Contraception
New 13-Cycle Vaginal Contraceptive System
The Future of Family Planning in Post-COVID America
New ASCCP Guidelines: Implications for FP
On the alert: mood disorders during 2020 stressors
Challenges old and new during the pandemic
Reproductive health in the time of Covid-19
Missed Pills: The Problem That Hasn’t Gone Away
Find the “yes! . . . and” rather than “no” or “but”
Digital Family Planning: the Future is Now
Irregular Bleeding Due to Contraceptives
Ouch! Best approaches to menstrual pain
Contraceptive efficacy: understanding how user and method characteristics play their part
Strategizing treatment for chronic heavy menstrual bleeding
Untangling the literature on obesity and contraception
High tech apps for no-tech FABM
Menstrual exacerbation of other medical conditions
From Princeton University: Thomas James Trussell (1949-2018)
The Short and Long of IUD Use Duration
Selecting a Method When Guidance Isn’t Clear-cut
Healthcare in the Time of Digital Expansion
The Scoop on Two New FDA-Approved Contraceptive Methods
Pregnancy of unknown location—meeting the challenge
Big “yes” (with caveats) to CHCs during perimenopause
The role of IUDs (LNG IUDs, too!) in emergency contraception
Combined pills’ effect on mood disorders
Abortion in the U.S.: safe, declining, and under threat
Hope for ovarian cancer screening test
Breast cancer still a small risk with some hormonal contraceptives
Record rate of HPV-related throat cancer
Viruses in semen potentially transmissible
Don’t Abstain from Your Role in Abstinence
Teens births declining but geographic ‘hotspots’ defy trend
Online Medical Abortion Service Effective and Safe
Do Women Really Need to Wait That Long?
Reassuring news on depression and OC use
PMDD: Genetic clues may lead to improved treatment
Breast cancer risk when there is a family history
Body weight link to breast and endometrial cancers (and 11 others)
Family Planning in 2017 and Beyond
Make Me Cry: Depression Link (Again)?
Managing implant users’ bleeding and spotting
Zika: Updated guidance for providers
Pharmacist-prescribed contraceptives
Hot off the press! 2016 MEC and SPR
Zika virus fears prompt increased request for abortion in nations outlawing abortions
Opioid use epidemic among reproductive-age women
Good news on the family planning home front!
War Against Planned Parenthood Hurts Women
Win-win for both treatment and prevention
Menopause, mood, mental acuity, and hormone therapy
Emergency contraception for teens
Postpartum Contraception: Now, Not Later
Are we practicing what we preach?
Be alert to VTE in hormonal contraceptive users
LARC among teens increased 15-fold, but not enough
Brain cancer and hormonal contraception
Free tools: Easy access to the US Medical Eligibility Criteria for Contraceptive Use
Alcohol consumption when pregnancy is unwanted or unintended
Latest Data on Contraceptive Use in the United States
LateBreaker sampler from Contraceptive Technology conference
Emergency Contraceptive Pill Efficacy and BMI/Body Weight
Handout on Unintended Pregnancy and Contraceptive Choice
Ask About Withdrawal (Really!)
Rules to Practice By: Safety First and Cleanliness is Close to. . .
What’s Vanity Fair Got Against the NuvaRing?
Promising New Treatment for Hepatitis C
Numbers matter, so make them simple for patients
The Recession’s Effect on Unintended Pregnancies
Lessons Learned from the Contraceptive CHOICE Project: The Hull LARC Initiative
Applying the “New” Cervical Cytology Guidelines in Your Practice
Acute Excessive Uterine Bleeding: New Management Strategies
Medical indications for IUD use in teens

While most patients with depression and related disorders will do well on most types of combined oral contraceptives, some have difficulty finding a satisfactory pill. For these patients, consider progestin type, phasic dosing, and extended or continuous regimens, say Kelli Stidham Hall and Julia R. Steinberg in the upcoming 21st edition of Contraceptive Technology, available September 2018.[1]
Family planning providers, who are often the sole source of healthcare for reproductive-aged women, are uniquely well-suited to address interrelated mental and reproductive health needs. In a brand new chapter on mental health and contraception, Hall and Steinberg write that contraception should be situated in the broader context of patients’ mental, physical, and reproductive health and wellbeing.
Most patients with depression and related disorders will do well on most types of combined oral contraceptives (COCs), and in fact research has suggested that the experiences of women with perceived side effects are generally similar across the many different available formulations of COCs (there are more than 90 different Food and Drug Administration (FDA)-approved COCs in the U.S. alone).[2],[3],[4] Contraceptive counseling should emphasize this point. However, several theoretical considerations may be useful in helping patients select the most suitable formulation, particularly for those patients who may have difficulty finding a satisfactory pill.
Progestin type, phasic dosing, and extended or continuous regimens are other considerations for COC selection among patients with depression and related conditions. A recent comprehensive review found that COCs containing less androgenic progestins may be less likely to contribute to mood symptoms compared to pills with higher androgenic properties.[5] Fourth-generation drospirenone-containing COCs have an FDA-approved indication for treatment of premenstrual dysphoric disorder (PMDD)-related mood symptoms and thus may be beneficial for some patients with depression and anxiety disorders.4 Levonorgestrel- and norgestrel-containing COCs (second generation) are not known to contribute to mood symptoms, and given their widespread use, also offer suitable options.[6],[7],[8] Many of these progestins are available in various phasic dosages, which could have relevance for cyclic mood symptoms due to variable circulating estrogen levels during ovulation and menses. For patients with cyclic mood concerns, monophasic formulations offer a steady dose (versus triphasic or 4-phasic formulations) to better stabilize hormone levels and minimize the risk of mood symptoms.8,[9] Patients who report mood symptoms during their placebo week (i.e., estrogen withdrawal) may benefit from COCs with extended cycle regimens (e.g., 24/4) or continuous dosing (i.e. skipping inactive pills), which would reduce or eliminate the estrogen withdrawal period.9
See Table 1 for strategies on counseling patients with mental health concerns.
Hall and Steinberg advise that, for the most part, a patient-provider shared decision-making process should inform contraceptive method selection based upon the patient’s individual health circumstances, contraceptive preferences, and family planning needs, rather than a mental health diagnosis or treatment. Drug interactions between modern pharmacologic antidepressant agents and hormonal contraceptives are relatively rare, and the best available scientific evidence suggests selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) do not interact with hepatic metabolism of synthetic steroids in COCs or other locally acting hormonal contraceptives.[10],[11]
You can read more about contraception and mental health in the 21st edition of Contraceptive Technology, due out in September 2018. Click here for ordering information.
Table 1. Contraceptive counseling strategies in consideration of mental health |
|
|
|
|
|
|
|
[1] Hall KS, Steinberg JR. Mental Health and Contraception. Hatcher RA, Nelson A, Trussell J, et al. Contraceptive Technology, 21st edition. New York, NY: Ayer Company Publishers, Inc. In production.
[2] Moreau C, Trussell J, Gilbert F, Bajos N, Bouver J. Oral contraceptive tolerance: does the type of pill matter? Obstet Gynecol 2007;109:1277-85.
[3] Hall KS, Trussell J. Types of combined oral contraceptives used by US women. Contraception 2012:86:659-65.
[4] Hatcher RA, Trussell J, Stewart F, et al. Contraceptive technology, 20th revised edition. New York, Ardent Media, 2004.
[5] Schaffir J, Worly BL, Gur T. Combined hormonal contraception and its effects on mood: a critical review. Eur J Contraception Reprod Health Care 2016;21:347-355.
[6] Maitra NN, Kulier R, Bloemenkamp K, Helmerhorst FM, Gulmezogul AM. Progestogens in combined oral contraceptives for contraception. Cochrane Database Syst Rev 2004;3:CD004861.
[7] Lawrie TA, Helmerhorst FM, Maitra NN, Kulier R, Bloemenkamp K, Gulmezoglu AM. Types of progestogens in combined oral contraception: effectiveness and side-effects Cochrane Database Syst Rev 2011;5:CD004861.
[8] Van Vliet HAAM, Grimes DA, Lopez LM, Schulz KF, Helmerhorst FM. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2011;11:CD003553.
[9] Edelman A, Gallo MF, Jensen JT, Nichols MD, Grimes DA. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev 2014;7:CD004695.
[10] Koke SC, Brown EB, Miner CM. Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy. Am J Obstet Gynecol 2002;187:551-5.
[11] D’Arcy PF. Drug interactions with oral contraceptives. Drug Intell Clin Pharm 1986;20:353-62.